Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbuster land. The FDA cleared the med for use in HER2-positive stomach cancer patients who previously received Roche’s standard-of-care Herceptin.
Last week, Pfizer and BioNTech said they were boosting vaccine production to 2 billion doses this year. There's a catch, though: Scaling up a factory in Belgium to help meet that goal means supplies will run short temporarily.